Case Report

Diagnosing a Gastric Submucosal Tumor Using Jumbo Biopsy “Unroofing” Technique: A Case Report and Review of the Literature

Sakshi Kapur,¹ Pradeep Mahal,² Levin Miles,³ and Adnan Hussain¹

¹ Department of Internal Medicine, Overlook Medical Center, 99 Beauvoir Avenue, Summit, NJ 07902, USA

² Division of Gastroenterology, Overlook Medical Center, Summit, NJ 07902, USA

³ Division of Pathology, Overlook Medical Center, Summit, NJ 07902, USA

Correspondence should be addressed to Sakshi Kapur; drcheenakapur@yahoo.co.in

Received 29 August 2013; Accepted 8 October 2013

Academic Editors: F. J. Kubben and R. Palmirotta

Copyright © 2013 Sakshi Kapur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report a case of a 40-year-old female who presented with dyspeptic symptoms for six months. Upper GI endoscopy revealed a submucosal nodule in gastric antrum. Using “jumbo biopsy unroofing technique” we were able to get adequate tissue for analysis. Histopathology revealed a type III gastric carcinoid. Patient was treated with laparoscopic distal subtotal gastrectomy with Roux-en-Y reconstruction and partial omentectomy. Although there was no evidence of metastasis on initial presentation, eighteen months later, patient was found to have multiple metastatic lesions in her liver. Patient’s lesions were treated with *intra-arterial (hepatic artery) Yttrium-90*.

1. Introduction

Gastric submucosal tumors are a common incidental finding occurring on routine upper GI endoscopies. Although different modalities for diagnosing these tumors are available, definitive diagnosis requires tissue analysis. Tissue acquisition for gastric submucosal tumors can be challenging. We report a case of a 40-year-old female who presented with dyspeptic symptoms. Upper GI endoscopy revealed a submucosal nodule in gastric antrum. Histopathology was compatible with a type III gastric carcinoid. Although there was no evidence of metastasis on initial presentation, eighteen months later, patient was found to have multiple metastatic lesions in her liver. Our case highlights the malignant potential of a gastric submucosal nodule, which may otherwise present as an incidental finding on upper GI endoscopy.

2. Case Presentation

A 40-year-old female presented with dyspeptic symptoms for six months. She denied any nausea, vomiting, or change in bowel habits. There was no history of hematemesis, melena,

or weight loss. Physical examination revealed an obese female with normal vital signs. Head and neck exam was positive for mild pallor but no icterus, thyromegaly, or lymph node enlargement was noted. Abdomen was soft, nontender with no hepatosplenomegaly.

Workup revealed a Hb of 11 gm/dL, white blood count of 11000/ μ L, and a platelet count of 2.26×10^3 / μ L. Blood urea nitrogen, creatinine, and electrolytes were normal.

Patient underwent an esophagogastroduodenoscopy and was found to have a *Helicobacter pylori* related chronic active gastritis. Concurrently, a submucosal mass measuring about 2.0 cm was noted in the gastric antrum (Figure 1).

Using jumbo biopsy “unroofing” technique, we were able to get extensive biopsies of this mass, and results revealed a well differentiated neuroendocrine tumor (NET) consistent with a gastric carcinoid (Figures 2 and 3). Subtyping confirmed a type III gastric carcinoid.

Subsequently, an endoscopic ultrasound (EUS) was done that confirmed a submucosal mass slightly smaller in size than initially anticipated, arising from the third layer, and no lymphadenopathy. Biomarkers for carcinoid such as serotonin, chromogranin A, and 5-HIAA were also negative.

FIGURE 1: Esophagogastroduodenoscopy showing a submucosal nodule in gastric antrum.

FIGURE 2: A well-differentiated neuroendocrine tumor consistent with carcinoid seen.

Computer tomography of the abdomen revealed gastric antral thickening secondary to carcinoid and no evidence of extragastric extension, liver, or adrenal metastasis.

Patient was treated with laparoscopic distal subtotal gastrectomy with Roux-en-Y reconstruction and partial omentectomy. Biopsy results confirmed a well-differentiated neuroendocrine tumor (NET) consistent with type III gastric carcinoid, restricted to submucosa, without involvement of

the muscularis propria (Figure 4). Twenty-two lymph nodes (17 in greater curvature and 5 in lesser curvature) were negative for metastasis, and the omentum was also benign.

Postoperatively, patient did well but complained of some nausea. An upper gastrointestinal series was performed, which ruled out leakage from the anastomotic site (Figure 5). Patient tolerated the diet well and was discharged from the hospital.

FIGURE 3: A well-differentiated neuroendocrine tumor consistent with carcinoid seen.

FIGURE 4: A well-differentiated neuroendocrine tumor consistent with a gastric carcinoid.

FIGURE 5: Contrast seen flowing from distal esophagus into remaining stomach without leakage from the anastomotic site.

Eighteen months later, patient presented to the hospital with progressively worsening generalized abdominal pain for one month. She complained of occasional nausea but denied any change in her appetite or weight. Physical examination was unremarkable. Computer tomography of the abdomen showed multiple, small, ill-defined, and low attenuating lesions in the left lobe of liver and a 1.7 cm mass in small bowel mesentery (Figure 6).

Magnetic resonance imaging revealed several hepatic lesions, with the largest lesion measuring 2.1×1.4 cm in left lobe of liver. Multiple lymph nodes in small bowel mesentery and porta hepatis were also enlarged (Figure 7).

A computer tomography guided core biopsy of hepatic lesions was performed, and results confirmed metastatic lesions, secondary to gastric carcinoid (Figure 8). Patient was treated with intra-arterial (hepatic artery) Yttrium-90.

Patient has been following with us for over two years, and her lesions have been stable so far.

3. Discussion

Gastric submucosal tumors (SMTs) are a common incidental finding occurring on routine upper GI endoscopies. The exact prevalence of these lesions is uncertain, although one retrospective study reported an incidence of 0.36% [1].

The differential ranges from benign lesions such as fibroma, lipoma, leiomyoma, varices, and heterotopic pancreas to malignant or potentially malignant lesions like lymphoma, gastrointestinal stromal tumors (GISTs), carcinoid, neurofibroma, schwannoma, and so forth. Extraluminal compression secondary to visceral structures can also appear as a submucosal nodule on endoscopy. The most common source of extraluminal compression is from spleen and splenic vessels [2]. Although the differential is very wide, definitive diagnosis depends upon tissue histopathology.

Certain risk criteria for malignancy in a submucosal nodule have been established on EUS. These include size > 3 cm, inhomogeneous echo pattern, irregular margins, and

presence of lymph nodes [3]. EUS has 64% sensitivity and 80% specificity in diagnosing malignant SMTs, when at least two of these criteria are present [4]. Lesions such as lipoma, heterotopic pancreas, and duplication cyst have a characteristic appearance on EUS [3]. However, hypoechoic lesions such as leiomyoma, GIST, carcinoid, and schwannomas need tissue diagnosis for confirmation. EUS can differentiate a real SMT from extraluminal compression caused by visceral organs. EUS examination of the gastric wall typically exhibits five layers. EUS can also help us determine the exact layer of origin of a SMT. Lesions arising from third and fourth echo layers have a high probability of being malignant and warrant a tissue diagnosis.

Cross-sectional imaging like CT and MRI can be used to evaluate the extent of metastasis for malignant tumors like GIST [5]. However, cross-sectional imaging unlike EUS does not offer the advantage of identifying the exact layer of origin of a submucosal nodule.

Gastric carcinoids are rare lesions that constitute less than 1% of all stomach neoplasms. They arise from enterochromaffin-like cells lining the gastric mucosa. Carcinoids can be subtyped into three categories. Type I and type II carcinoid account for 80% of these lesions and are associated with atrophic gastritis and Zollinger Ellison syndrome respectively. Management includes endoscopic resection followed by endoscopic surveillance. Type III carcinoid accounts for 15–20% of these tumors and has the highest rate of metastases ($>50\%$). Most of these tumors are metastatic at the time of presentation. Treatment of this subtype requires surgical resection. On endoscopy, carcinoids appear as polypoid masses with a normal overlying mucosa [6]. They usually arise from second or third layer on EUS. Adequate sampling and subsequent subtyping not only help us in making a definitive diagnosis, but also help us to choose the correct treatment modality for these patients.

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract. The annual incidence is estimated to be at least 10 to 20 cases per million [7]. Most GISTs are positive for C-KIT and CD 34

FIGURE 6: Heterogeneous liver with multiple low attenuating foci and a soft tissue density seen in small bowel mesentery.

FIGURE 7: Numerous hepatic lesions seen, with the largest lesion at the dome of the lateral segment of left lobe of liver measuring 2.1×1.4 cm; multiple enlarged lymph nodes in small bowel mesentery and porta hepatis also seen.

staining and are thought to arise from interstitial cell of Cajal. GI autonomic nerve tumors (GANTs) are also categorized under GISTs owing to their immunohistochemical resemblance. 65% of the GISTs occur in stomach and appear as submucosal nodules on upper GI endoscopy. Up to 10% to 30% of GISTs are malignant. However, recent data suggests that all GISTs have a malignant potential [8]. On EUS examination, GISTs typically arise from the fourth layer, and size, irregular borders, lobulation, and echogenic foci indicate malignancy [9]. Endoscopic differentials include gastric lymphoma and inflammatory fibroid polyp [10]. Therefore, tissue

diagnosis of a submucosal nodule should not only be able to differentiate a GIST from a non-GIST, but also evaluate the malignant potential of this tumor.

Tissue acquisition for a gastric SMT can be challenging. The yield of standard endoscopy is usually poor [1]. EUS guided fine needle aspiration (FNA) can be used to obtain tissue, but the yield is often inadequate to make a definitive diagnosis, especially for mesenchymal tumors and when differentiation between benign and malignant stromal tumors is needed [11]. Tissue yield of EUS-FNA ranges from 50% to 93% [11, 12]. In a prospective study by Turhan et al.,

FIGURE 8: Liver biopsy consistent with metastatic gastric carcinoid.

the sensitivity, specificity, positive and negative predictive values, and accuracy of EUS-FNA for diagnosing submucosal mesenchymal tumors of upper GI tract were 82.9%, 73.3%, 87.9%, 64.7%, and 80%, respectively. The corresponding values for nonmesenchymal lesions were 100%, 85.7%, 80%, 100%, and 90.9% [13].

Although cytological examination is usually sufficient to make a diagnosis of GIST, differentiation between benign and malignant stromal tumors requires histopathological and immunochemical analysis. Pathological assessment of GIST requires immunohistochemical staining for c-KIT (CD 117). 95% of GISTs are positive for C-KIT. Immunohistochemical stains can also be used to differentiate GISTs from endoscopic differentials like lymphoma and inflammatory polyp. However, there are some GISTs that are negative for C-KIT. In these tumors, DOG 1 gene expression can be used. DOG 1 has a greater sensitivity as compared to C-KIT [14, 15]. Ki-67 labeling index has also been used to differentiate benign from malignant GISTs. In a study conducted by Ando et al. and Liu et al., the accuracy for Ki-67 in predicting the aggressiveness of GIST was over 90% [16, 17].

Various factors such as size of lesion, site (lesions in lower third of stomach are difficult to sample), number of needle passes, on-site cytopathologist, and cytological versus histopathological assessment can affect the outcome of EUS-FNA. Side effects of EUS-FNA include bleeding and infections. EUS Doppler before EUS-FNA can prevent rupture of a varix, which otherwise might be mistaken for a submucosal nodule [18].

EUS guided trucut needle biopsy (TCB) has been used for acquisition of core tissue specimens. Procedural difficulties such as needle stiffness and lesions in distal stomach can pose challenge for an endoscopist. The combination of both EUS-FNA and EUS TCB has been found to be superior to either technique alone [19]. Combining these two methods has

shown to increase the diagnostic accuracy to 95%, without an immediate cytopathologist [19].

Jumbo biopsy forceps can be used for obtaining tissue from deeper layers of the gastric wall. In a retrospective study by Buscaglia et al., out of the 129 patients with subepithelial lesions of the upper and lower GI tract that underwent EUS with biopsy using jumbo forceps, 58.9% of patients had a definitive diagnosis [20]. The results in third layer (EUS) were the most definitive. However, 34.9% of patients experienced significant bleeding and required some form of endoscopic hemostasis [20]. In another study by Komanduri et al., out of the 66 patients that underwent jumbo biopsy “unroofing technique” for tissue acquisition, 92% provided adequate tissue, without significant complications [21, 22]. Jumbo biopsy forceps along with on-site “touch preparation cytology” have shown to further increase the accuracy [22]. Therefore, use of jumbo biopsy forceps for tissue acquisition seems to be a safe and effective option for diagnosing gastric SMTs.

4. Conclusion

Tissue diagnosis of a gastric SMT can be challenging. Use of jumbo biopsy “unroofing technique” seems to be an attractive option for diagnosing these tumors. On-site “touch preparation cytology” has shown to further increase the accuracy.

Conflict of Interests

The authors declare that they have no conflict of interests.

References

- [1] J. L. Hedenbro, M. Ekelund, and P. Wetterberg, “Endoscopic diagnosis of submucosal gastric lesions—the results after routine endoscopy,” *Surgical Endoscopy*, vol. 5, no. 1, pp. 20–23, 1991.
- [2] Y. Motoo, T. Okai, H. Ohta et al., “Endoscopic ultrasonography in the diagnosis of extraluminal compressions mimicking gastric submucosal tumors,” *Endoscopy*, vol. 26, no. 2, pp. 239–242, 1994.
- [3] B. Landi and L. Palazzo, “The role of endosonography in submucosal tumours,” *Best Practice and Research*, vol. 23, no. 5, pp. 679–701, 2009.
- [4] T. Rösch, B. Kapfer, U. Will et al., “Accuracy of endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a prospective multicenter study,” *Scandinavian Journal of Gastroenterology*, vol. 37, no. 7, pp. 856–862, 2002.
- [5] S. Hasegawa, R. C. Semelka, T. C. Noone et al., “Gastric stromal sarcomas: correlation of MR imaging and histopathologic findings in nine patients,” *Radiology*, vol. 208, no. 3, pp. 591–595, 1998.
- [6] S. Nakamura, M. Iida, T. Yao, and M. Fujishima, “Endoscopic features of gastric carcinoids,” *Gastrointestinal Endoscopy*, vol. 37, no. 5, pp. 535–538, 1991.
- [7] M. S. Saund, G. D. Demetri, and S. W. Ashley, “Gastrointestinal stromal tumors (GISTs),” *Current Opinion in Gastroenterology*, vol. 20, no. 2, pp. 89–94, 2004.
- [8] J. K. Trupiano, R. E. Stewart, C. Misick, H. D. Appelman, and J. R. Goldblum, “Gastric stromal tumors: a clinicopathologic

- study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors,” *American Journal of Surgical Pathology*, vol. 26, no. 6, pp. 705–714, 2002.
- [9] A. Chak, M. I. Canto, T. Rosch et al., “Endosonographic differentiation of benign and malignant stromal cell tumors,” *Gastrointestinal Endoscopy*, vol. 45, no. 6, pp. 468–473, 1997.
- [10] K. Zinkiewicz, W. Zgodziński, A. Dbrowski, J. Szumio, G. Ąwik, and G. Wallner, “Recurrent inflammatory fibroid polyp of cardia: a case report,” *World Journal of Gastroenterology*, vol. 10, no. 5, pp. 767–768, 2004.
- [11] M. A. Mekky, K. Yamao, A. Sawaki et al., “Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors,” *Gastrointestinal Endoscopy*, vol. 71, no. 6, pp. 913–919, 2010.
- [12] M. Matsui, H. Goto, Y. Niwa, T. Arisawa, Y. Hirooka, and T. Hayakawa, “Preliminary results of fine needle aspiration biopsy histology in upper gastrointestinal submucosal tumors,” *Endoscopy*, vol. 30, no. 9, pp. 750–755, 1998.
- [13] N. Turhan, G. Aydog, Y. Ozin, B. Cicek, M. Kurt, and D. Oguz, “Endoscopic ultrasonography-guided fine-needle aspiration for diagnosing upper gastrointestinal submucosal lesions: a prospective study of 50 cases,” *Diagnostic Cytopathology*, vol. 39, no. 11, pp. 808–817, 2011.
- [14] D. G. Hwang, X. Qian, and J. L. Hornick, “DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks,” *American Journal of Clinical Pathology*, vol. 135, no. 3, pp. 448–453, 2011.
- [15] C. Wang, M. S. Jin, Y. B. Zou et al., “Diagnostic significance of DOG-1 and PKC- θ expression and c-Kit/PDGFR mutations in gastrointestinal stromal tumours,” *Scandinavian Journal of Gastroenterology*, vol. 48, no. 9, pp. 1055–1065, 2013.
- [16] N. Ando, H. Goto, Y. Niwa et al., “The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis,” *Gastrointestinal Endoscopy*, vol. 55, no. 1, pp. 37–43, 2002.
- [17] L. C. Liu, W. T. Xu, X. Wu, P. Zhao, Y. L. Lv, and L. Chen, “Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors,” *World Journal of Gastroenterology*, vol. 19, no. 16, pp. 2473–2480, 2013.
- [18] H. Sakamoto, M. Kitano, and M. Kudo, “Diagnosis of subepithelial tumors in the upper gastrointestinal tract by endoscopic ultrasonography,” *World Journal of Radiology*, vol. 2, no. 8, pp. 289–297, 2010.
- [19] I. Storch, M. Jorda, R. Thurer et al., “Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination,” *Gastrointestinal Endoscopy*, vol. 64, no. 4, pp. 505–511, 2006.
- [20] J. M. Buscaglia, S. Nagula, V. Jayaraman et al., “Diagnostic yield and safety of jumbo biopsy forceps in patients with subepithelial lesions of the upper and lower GI tract,” *Gastrointestinal Endoscopy*, vol. 75, no. 6, pp. 1147–1152, 2012.
- [21] S. Komanduri, L. Keefer, and S. Jakate, “Diagnostic yield of a novel jumbo biopsy unroofing technique for tissue acquisition of gastric submucosal masses,” *Endoscopy*, vol. 43, no. 10, pp. 849–855, 2011.
- [22] R. N. Keswani, R. Nayar, A. Mahajan, and S. Komanduri, “Touch preparation of jumbo forceps biopsies allows rapid adequacy assessment of subepithelial GI masses,” *Gastrointestinal Endoscopy*, vol. 74, no. 2, pp. 411–414, 2011.